Nemysis
With a specific emphasis on preserving the microbiome , Nemysis developed an iron-based nano-particulate compound to address the effects caused by iron deficiency as well as the currently available therapeutic solutions. Celiac Disease (CD) and Non-Celiac Gluten Sensitivity (NCGS) are two distinct conditions whereby the ingestion of gluten and other components of wheat leads to a series of serious gastro-intestinal and other severe reactions. E40 is a new Glutenase, developed to specifically address these conditions.
Nemysis operate a diversified, independent platform with multi-product capabilities. In the short term they take products through the novel food supplement or medical device route, but with a longer term plan to take these compounds to drug status and to be phase II, ready to out-license products for drug development for the prescriptions market. In order to do this all their pre-clinical, clinical and manufacturing development activities are carried out, through any development stage, in GLP and GMP standard.
Nemysis’ immediate plans are to complete development and commercialise novel technologies, for use in nutritional deficiency, that are both effective and gentle on the patients gut microbiome and preserving its integrity.
